Day 1

Gain insight into today’s sessions so you can get the most out of your conference experience.

Understand the priorities of the CDA-AMC’s expanded role in 2025 and its direction into 2026. Assess the impact of this development on your organization by learning about the existing and emerging core functions of Canada’s Drug Agency. Walk away with an action plan on:

• Leading national efforts on a pan-Canadian appropriate use and prescribing program.
• Enhancing patient experience through data and analytics.
• Improving system coordination across Canada.

Advance your market access strategy with direct guidance from the CDA-AMC to align with national priorities and support equitable access for patients across Canada.

Dive into the evolving landscape of National Pharmacare and its implications for nationwide efforts towards achieving affordable, equitable access to medications across Canada. Source your plan of action with insights on:

• National Pharmacare aiming to unify drug coverage, reduce disparities, and improve affordability for all Canadians.
• Key challenges involving balancing cost-containment with innovation and aligning federal-provincial priorities.
• Stakeholder collaboration from payers to patients being essential for sustainable and equitable access models.

Achieve a comprehensive understanding of the national pharmacare debate and how to prepare for future policy to navigate evolving healthcare landscapes and drive equitable access to medications across Canada.

Canada’s vaccine landscape is evolving but ensuring equitable access across the country’s various jurisdictions is not without its hurdles.

This expert panel will bring together participants with diverse backgrounds and perspectives from Canadian healthcare to share viewpoints, discuss actionable strategies, and explore innovative ideas that could reshape the future of vaccine access.

• Demystify the patchwork for access: Understand the intricacies of provincial and territorial funding and procurement and how to build more cohesive, nationally aligned access strategies
• Redefine Value: Explore evolving HTA and value assessment methods for vaccines, and how to measure the broader public health and societal benefits of vaccines for adults and their role in preventive care
• Expand Access: Tackle the persistent barriers to adult immunization and travel-related vaccines and explore new pathways to broaden coverage.

Whether you’re navigating policy, pricing, or patient access, this session will equip you with the insights and tools to drive meaningful change in vaccine market access across Canada.

The definition of ‘value’ as it pertains to market access in Canada can differ depending on the stakeholder perspective. Gain clarity on defining your value. Adopt best practices to:

• Understand how Health Canada approvals and INESSS assessments shape value perceptions.
• Align value propositions with public and private insurers, patient advocacy groups, and healthcare providers, ensuring alignment with national and provincial reimbursement frameworks.
• Leverage health economic models, patient outcomes data, and comparator analyses to demonstrate value beyond pricing.

Reduce misalignment among stakeholders by clarifying value in pricing and reimbursement discussions.

• Browse through different sponsor booths and source innovative market access expertise.
• Enter your name for a chance to win exciting prizes.
• Take advantage of event-specific offers and special content.

The landscape of market access for pharmaceutical and healthcare is rapidly changing, presenting both pitfalls and opportunities for the industry to meet patient needs. Understanding key risks and proactively identifying growth opportunities is essential for long-term success. Develop a blueprint to:

• Assess the impact of regulatory changes and explore how the industry can engage effectively with regulators.
• Identify emerging opportunities for growth and innovation and examine how they can enhance patient access.
• Develop strategies to mitigate risks and capitalize on key trends by leveraging data-driven insights, stakeholder collaboration, and adaptive business models.

Bolster your ability to navigate a dynamic pharmaceutical environment to identify emerging opportunities, mitigate evolving risks, and strengthen patient access across Canada.

• Visit sponsor booths and experience the next level of market access innovation
• Meet one-on-one with leading solution providers to discuss organizational hurdles.
• Brainstorm solutions and gain new perspectives and ideas.

Hear the latest update on draft guidelines detailing the administrative process for recommending hearings on excessive drug pricing, to enhance transparency and procedural fairness in assessing whether a patented medicine’s price is excessive. Adopt best practices to:

• Learn directly from the PMPRB on how the draft guidelines and recommendations have been asserted.
• Gain clarity on the PMPRB’s interim guidance aimed at expediting price reviews and its impact on market entry timelines.

Master the roadmap for 2026 and beyond in PMPRB strategy to improve pricing processes and ensure timely market access for innovative medicines.

Content to include:

• Data & evidence generation
• RWE
• PSP
• Market Access & Reimbursement

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!